| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC22383 | Sitaxsentan | A potent, long acting, orally active, selective ETA receptor antagonist that binds competitively to human ETA receptor with Ki of 0.43 nM, IC50 of 1.4 nM. |
|
| DC23661 | Evogliptin | A potent, long acting, reversible and competitive DPP-4 inhibitor with IC50 of 0.9 nM. |
|
| DC22890 | Frovatriptan Featured | A potent, long lasting 5-HT(1B/1D) receptor agonist as a antimigraine agent.. |
|
| DC22812 | CEP-11981 | CEP-11981 is a potent, multi-targeted, orally active, pan-VEGFR, TIE-2 and FGFR1 inhibitor with IC50 of 3-100 nM. |
|
| DC22851 | IDI-6273 | A potent, mutant-selective PfDHODH inhibitor with IC50 of 210 nM for 3D7 E182D PfDHODH. |
|
| DC20946 | DD-01050 | A potent, noncompetitive TRPV1 antagonist that abrogates capsaicin and pH-evoked TRPV1 channel activity with submicromolar activity. |
|
| DC24010 | Plpro-IN-6(PLpro inhibitor) Featured | A potent, noncovalent SARS-CoV papain-like protease (PLpro) inhibitor with IC50 of 2.6 uM. |
|
| DC22706 | BMY 45778 Featured | A potent, non-prostanoid prostacyclin partial agonist that potently inhibits human (IC50=35 nM), rabbit (IC50=136 nM) and rat (IC50=1.3 uM) platelet aggregation. |
|
| DC22815 | K252a | A potent, non-selective tyrosine protein kinase inhibitor for Trk family, CaMK and other phosphorylase kinases. |
|
| DC20615 | A 834735 | A potent, nonselective, brain penetrant, full agonist at both the central CB1 and peripheral CB2 receptors with Ki of 4.6 and 0.31 nM, respectively. |
|
| DC22899 | MK-3577 | A potent, oral active glucagon receptor antagonist blocking the glucagon effect for the treatment of T2DM. |
|
| DC23709 | FXR-sHE modulator 57 | A potent, orally active dual modulator of FXR and soluble epoxide hydrolase (sEH) that exertss partial FXR agonism (pEC50=7.7) and sEH inhibitory activity (pIC50=8.4). |
|
| DC23968 | GAP-134 hydrochloride | A potent, orally active gap-junction modifier. |
|
| DC23969 | GAP-134 | A potent, orally active gap-junction modifier. |
|
| DC20972 | DS79182026 | A potent, orally active hepcidin production inhibitor with IC50 of 39 nM, with low kinase inhibitory activity. |
|
| DC20694 | ASP 9853 | A potent, orally active iNOS inhibitor (IC50=10 nM, NO release DLD-1 cells) that prevents dimerization of iNOS, but has no effect on the expression or enzyme activity of iNOS. |
|
| DC22737 | CP-346086 Featured | A potent, orally active microsomal triglyceride transfer protein (MTP) inhibitor that inhibits both human and rodent MTP with IC50 of 2 nM. |
|
| DC21627 | SC-806 | A potent, orally active p38 MAPK inhibitor with IC50 of 50 nM, significantly decreases incidence of arthritis in mouse collagen-induced arthritis.. |
|
| DC21288 | MK-8617 Featured | A potent, orally active pan-inhibitor of HIF prolyl hydroxylase (HIF-PHD) with IC50 of 1.0,1.0, and 14 nM for HIF-PHD1, 2, and 3, respectively. |
|
| DC22849 | DSM 74 | A potent, orally active PfDHODH inhibitor (IC50=0.3 uM) with antimalarial activity. |
|
| DC22704 | SN79 | A potent, orally active sigma receptor antaognist with Ki of 27 and 7 nM for σ1 and σ2, respectively. |
|
| DC22601 | BMS-433796 | A potent, orally active γ-secretase inhibitor with cell IC50 of 0.3 nM. |
|
| DC22853 | IDN-7314 | A potent, orally active, and irreversible pan-Caspase protease inhibitor with IC50 of <0.08 to 7 nM for inhibition of activated caspase 3, 6 and 8. |
|
| DC20807 | Gemopatrilat | A potent, orally available, dual ACE-neutral endopeptidase (vasopeptidase) inhibitor with IC50 of 12 and 63 nM, respectively. |
|
| DC21396 | Marizomib Featured | A potent, orally bioactive 20S proteasome inhibitor with IC50 of 1.3 nM (inhibition of proteasomal chymotrypsin-like proteolytic activity). |
|
| DC22598 | Rislenemdaz | A potent, orally bioavailable brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively, with no off-target activity. |
|
| DC23970 | SCH-563705 | A potent, orally bioavailable dual CXCR2/CXCR1 receptor antagonist with IC50 of 1.3 nM and 7.3 nM, respectively. |
|
| DC21541 | PSI-421 | A potent, orally bioavailable P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.. |
|
| DC24192 | Dasatinib hydrochloride | A potent, orally bioavailable, dual Src/Abl kinase inhibitor with IC50 of 0.5, 0.4, 0.5 and <1 nM for Src, Lck, Yes and Bcr-Abl, respectively. |
|
| DC21631 | MK-8242 | A potent, orally bioavailable, small-molecule inhibitor of HDM2/p53 protein-protein interaction. |
|
